Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment
Cardiovascular Research · 27.02.2024 · 120 (1) · 69-81
DOI: 10.1093/cvr/cvad182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 12.12.2023. Verfasst von Kalina Andrysiak und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Kraków, P…. Hauptthemen laut MEDLINE: Cardiomyopathies, Induced Pluripotent Stem Cells, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MAESTRO, National Science Centre, OPUS.
Abstract (Originalsprache)
Aims
Duchenne muscular dystrophy (DMD)-associated cardiomyopathy is a serious life-threatening complication, the mechanisms of which have not been fully established, and therefore no effective treatment is currently available. The purpose of the study was to identify new molecular signatures of the cardiomyopathy development in DMD. Methods and results For modelling of DMD-associated cardiomyopathy, we prepared three pairs of isogenic control and dystrophin-deficient human induced pluripotent stem cell (hiPSC) lines. Two isogenic hiPSC lines were obtained by CRISPR/Cas9-mediated deletion of DMD exon 50 in unaffected cells generated from healthy donor and then differentiated into cardiomyocytes (hiPSC-CM). The latter were subjected to global transcriptomic and proteomic analyses followed by more in-depth investigation of selected pathway and pharmacological modulation of observed defects. Proteomic analysis indicated a decrease in the level of mitoNEET protein in dystrophin-deficient hiPSC-CM, suggesting alteration in iron metabolism. Further experiments demonstrated increased labile iron pool both in the cytoplasm and mitochondria, a decrease in ferroportin level and an increase in both ferritin and transferrin receptor in DMD hiPSC-CM. Importantly, CRISPR/Cas9-mediated correction of the mutation in the patient-derived hiPSC reversed the observed changes in iron metabolism and restored normal iron levels in cardiomyocytes. Moreover, treatment of DMD hiPSC-CM with deferoxamine (DFO, iron chelator) or pioglitazone (mitoNEET stabilizing compound) decreased the level of reactive oxygen species in DMD hiPSC-CM.
Conclusion
To our knowledge, this study demonstrated for the first time impaired iron metabolism in human DMD cardiomyocytes, and potential reversal of this effect by correction of DMD mutation or pharmacological treatment. This implies that iron overload-regulating compounds may serve as novel therapeutic agents in DMD-associated cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Kraków, Poland.
- Laboratory of Bioinformatics and Genome Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
- Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.
- Department of Cell Biology and Imaging, Institute of Zoology and Biomedical Research, Faculty of Biology, Jagiellonian University, Kraków, Poland.
- Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
ORCID-Profile: Kalina Andrysiak, Jacek Stępniewski, Józef Dulak
Förderung
- MAESTRO
- National Science Centre
- OPUS
- Biochemistry, Biophysics and Biotechnology at Jagiellonian University
- Strategic Programme Excellence Initiative
Zitieren
APA
Andrysiak, K., Machaj, G., Priesmann, D., Woźnicka, O., Martyniak, A., Ylla, G., Krüger, M., Pyza, E., Potulska-Chromik, A., Kostera-Pruszczyk, A., Łoboda, A., Stępniewski, J., & Dulak, J. (2024). Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment. Cardiovascular Research, 120(1), 69-81. https://doi.org/10.1093/cvr/cvad182
Vancouver
Andrysiak K, Machaj G, Priesmann D, Woźnicka O, Martyniak A, Ylla G, et al. Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment. Cardiovascular Research. 2024;120(1):69-81. doi:10.1093/cvr/cvad182
BibTeX
@article{Andrysiak2024,
author = {Andrysiak, Kalina and Machaj, Gabriela and Priesmann, Dominik and Woźnicka, Olga and Martyniak, Alicja and Ylla, Guillem and Krüger, Marcus and Pyza, Elżbieta and Potulska-Chromik, Anna and Kostera-Pruszczyk, Anna and Łoboda, Agnieszka and Stępniewski, Jacek and Dulak, Józef},
title = {Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment},
journal = {Cardiovascular Research},
year = {2024},
volume = {120},
number = {1},
pages = {69--81},
doi = {10.1093/cvr/cvad182}
}
EUVIMED